Zhejiang Hisun Pharmaceutical (SHA:600267) unit Hisun Animal Health obtained veterinary drug approval from China's agriculture ministry for terbinafine hydrochloride tablets.
The drug, with brand name Fenlishu, is indicated for canine skin infections caused by Microsporum canis, according to a Tuesday filing with the Shanghai bourse.
The approval is valid until Feb. 13, 2031.
Shares of the company were down 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments